Diabetes in Indonesia: What Medicines do Physicians Prefer?

As concerns mount about Indonesia’s growing diabetes epidemic, many organizations are working to increase awareness and improve treatment of the disease. Yet good data on the burden of diabetes and patient treatment pathways remains limited. mClinica has several datasets that can help. One such dataset is based on a longitudinal sample of prescription information that […]

mClinica Wins Pierre Fabre Foundation Prize for E-health Innovation

Above: Jake Josol, mClinica’s Director of Software Services, with Mme Béatrice Garrette, Director General of the Pierre Fabre Foundation. On July 4, mClinica had the honor of receiving the Pierre Fabre Foundation Prize for e-health innovation. The prize was received at a conference hosted by the Pierre Fabre Foundation, a French organization dedicated to improving healthcare in […]

REPORT: Diabetes in Jakarta–Rx Market SnapShot 2016

With one of the largest diabetic patient populations in Asia and millions of undiagnosed cases, Indonesia poses both opportunities and challenges for healthcare organizations focused on diabetes. For those seeking insight on this topic, mClinica is pleased to present its first SnapShot report on Jakarta, Indonesia’s most important healthcare hub. Using mClinica’s proprietary prescription datasets, the […]

REPORT: Antibiotics in Jakarta–Rx Market SnapShot 2016

Antibiotics are one of the most widely prescribed types of medicines in Indonesia today, but data on their usage is not widely available. For healthcare organizations seeking insight on the current state of Indonesia’s antibiotics market, mClinica is pleased to present its first SnapShot report on the OOP market in Jakarta, Indonesia’s most important healthcare […]

How mClinica Can Support AMR Surveillance in Southeast Asia

As global health organizations ramp up efforts to fight the spread of drug-resistant microbes, many recognize a growing need to collect robust data on risk factors for antimicrobial resistance (AMR). At mClinica, we have data collection and patient engagement platforms that can help. We manage these platforms in Asia’s emerging markets. In the Philippines, Indonesia, […]

REPORT: Antibiotics in Ho Chi Minh City—Rx Market SnapShot 2016

Antibiotics are one of the most widely prescribed types of medicines in Vietnam today, but market dynamics for these critical medicines are not widely understood. For healthcare organizations seeking insight on the current state of Vietnam’s antibiotics market, mClinica is pleased to present its first SnapShot report on the OOP market in Ho Chi Minh […]

mClinica Wins USAID Award for Data-Driven Innovation

Above: mClinica Chief Digital Officer Will Greene receives the Data for Resilience Award at USAID’s regional headquarters in Bangkok. On May 11, we had the privilege of presenting at the Data for Resilience Summit, a conference on data-driven strategies for promoting sustainable development. The conference, which was hosted by USAID Asia and FHI360, included a […]

Diabetes in Ho Chi Minh City: Rx Trends Reveal Market Shifts

To address Vietnam’s growing diabetes epidemic, healthcare organizations must improve access to high-quality treatments. Efforts are needed throughout the country, but Ho Chi Minh City requires special attention. As Vietnam’s largest city, Ho Chi Minh City (HCMC) has more diabetics than anywhere else in the country. Incidence of the disease is significantly above the national […]

Diabetes Threatens Vietnam’s Healthcare Systems

Diabetes is a major problem in Vietnam today. It afflicts millions of people in the country, and incidence of the disease is growing at alarming rates. Addressing this problem will require improved measures to prevent, diagnose, and treat the disease. Public and private healthcare organizations need to act fast before it’s too late. On the […]

Southeast Asia’s Growing Diabetes Epidemic

Diabetes afflicts more than 25 million Southeast Asians today. As incidence of the disease grows across the region, healthcare systems face mounting pressures. Yet interventions designed for developed countries will have little impact in emerging markets like Indonesia, the Philippines, and Vietnam. To address the problem in places like these, healthcare organizations need better sources […]